Trial Profile
A Phase 1b Study of REOLYSIN (Reovirus Serotype 3 - Dearing Strain) Combined With Standard Doses of Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Pelareorep (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Proof of concept
- 05 Aug 2022 Planned End Date changed from 21 Feb 2023 to 21 Aug 2024.
- 05 Aug 2022 Planned primary completion date changed from 21 Feb 2022 to 21 Aug 2023.
- 08 Apr 2022 Results published in the Media Release